NCT05764538
DAOIB for the Treatment of Brain Fog
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Jun 2026 to Jun 2027
- Eligibility criteria expanded, about 11 words
- Primary endpoints: details revised at 1 of 1 entry
- Secondary endpoints: details revised at 7 of 7 entries
- Notable Primary and study completion dates: Feb 2025 to Jun 2026v3
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Timeframe: week 0, 8, 16, 24
Secondary (7)
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24
Change from baseline in Quality of life score at week 8, 16 and 24
Change from baseline of 17-item Hamilton Rating Scale for Depression
Change from baseline of Hamilton Anxiety Rating Scale
Show 2 moreShow less
Change from baseline of Perceived Stress Scale
Change from baseline in the score of a battery of additional cognitive tests
Arms and interventions
DAOIBExperimental
Drugs: DAOIB
Sites
1 site in 1 country
- Kaohsiung Chang Gung Memorial HospitalKaohsiung City, Taiwan